<p>Mati Gill, CEO of AION Labs, sits down with Amar Drawid to discuss how the AI venture studio works with its Big Pharma partners to define the biggest drug development hurdles the industry faces; and how it holds challenges to attract academics, entrepreneurs, and life sciences professionals with the best solutions to build new companies.</p>

Mati Gill, CEO of AION Labs, sits down with Amar Drawid to discuss how the AI venture studio works with its Big Pharma partners to define the biggest drug development hurdles the industry faces; and how it holds challenges to attract academics, entrepreneurs, and life sciences professionals with the best solutions to build new companies.

A Venture Studio with Big Pharma Backing Seeks to Fix Drug Development with AI

The Life Sciences D’n’A podcast is hosted by AI and data analytics experts and pharma industry veterans Nagaraja Srivatsan and Amar Drawid. They explore the evolving use of AI and data science with innovators working to reshape all aspects of the biopharmaceutical industry from the way new therapeutics are discovered to how they are marketed.

Share A Venture Studio with Big Pharma Backing Seeks to Fix Drug Development with AI

Sign up to save your podcasts

A Venture Studio with Big Pharma Backing Seeks to Fix Drug Development with AI

A Venture Studio with Big Pharma Backing Seeks to Fix Drug Development with AI